Browsing by Subject "peak inspiratory flow"

Now showing 1 - 2 of 2
  • No Thumbnail Available
    Item
    Inspiratory flow profile and usability of the NEXThaler, a multidose dry powder inhaler, in asthma and COPD
    (BioMed Central Ltd, 2021) Chetta A.; Yorgancioglu A.; Scuri M.; Barile S.; Guastalla D.; Dekhuijzen P.N.R.
    Background: Inhaler selection is important when managing respiratory conditions; a patient’s inhalation technique should be appropriate for the selected device, and patients should ideally be able to use a device successfully regardless of disease severity. The NEXThaler is a multidose dry-powder inhaler with a breath-actuated mechanism (BAM) and dose counter that activates only following inhalation, so effectively an ‘inhalation counter’. We assessed inspiratory flow through the NEXThaler in two studies and examined whether inhalation triggered the BAM. Methods: The two studies were open-label, single-arm, and single visit. One study recruited patients with asthma aged ≥ 18 years; the other recruited patients with chronic obstructive pulmonary disease (COPD) aged ≥ 40 years. All patients inhaled twice through a placebo NEXThaler. The inspiratory profile through the device was assessed for each inhalation using acoustic monitoring, with flow at and time to BAM firing, peak inspiratory flow (PIF), and total inhalation time assessed. Results: A total of 40 patients were enrolled in the asthma study: 20 with controlled asthma and 20 with partly controlled/uncontrolled asthma. All patients were able to trigger the BAM, as evidenced by the inhalation counter activating on closing the device. Mean flow at BAM firing following first inhalation was 35.0 (range 16.3–52.3) L/min; mean PIF was 64.6 (35.0–123.9) L/min. A total of 72 patients were enrolled in the COPD study, with data analysed for 69 (mean forced expiratory volume in 1 s 48.7% predicted [17–92%]). As with the asthma study, all patients, regardless of airflow limitation, were able to trigger the BAM. Mean flow at BAM firing following first inhalation was 41.9 (26.6–57.1) L/min; mean PIF was 68.0 (31.5–125.4) L/min. Device usability was rated highly in both studies, with 5 min sufficient to train the patients, and a click heard shortly after inhalation in all cases (providing feedback on BAM firing). Conclusions: Inhalation flows triggering the BAM in the NEXThaler were similar between patients with controlled and partly controlled/uncontrolled asthma, and were similar across COPD airflow limitation. All enrolled patients were able to activate the device. © 2021, The Author(s).
  • No Thumbnail Available
    Item
    The Allergic Rhinitis and Its Impact on Asthma (ARIA) Approach of Value-Added Medicines: As-Needed Treatment in Allergic Rhinitis
    (American Academy of Allergy, Asthma and Immunology, 2022) Bousquet J.; Toumi M.; Sousa-Pinto B.; Anto J.M.; Bedbrook A.; Czarlewski W.; Valiulis A.; Ansotegui I.J.; Bosnic-Anticevich S.; Brussino L.; Canonica G.W.; Cecchi L.; Cherrez-Ojeda I.; Chivato T.; Costa E.M.; Cruz A.A.; Del Giacco S.; Fonseca J.A.; Gemicioglu B.; Haahtela T.; Ivancevich J.C.; Jutel M.; Kaidashev I.; Klimek L.; Kvedariene V.; Kuna P.; Larenas-Linnemann D.E.; Lipworth B.; Morais-Almeida M.; Mullol J.; Papadopoulos N.G.; Patella V.; Pham-Thi N.; Regateiro F.S.; Rouadi P.W.; Samolinski B.; Sheikh A.; Taborda-Barata L.; Ventura M.T.; Yorgancioglu A.; Zidarn M.; Zuberbier T.
    Drug repurposing is a major field of value-added medicine. It involves investigating and evaluating existing drugs for new therapeutic purposes that address unmet healthcare needs. Several unmet needs in allergic rhinitis could be improved by drug repurposing. This could be game-changing for disease management. Current medications for allergic rhinitis are centered on continuous long-term treatment, and medication registration is based on randomized controlled trials carried out for a minimum of 14 days with adherence of 70% or greater. A new way of treating allergic rhinitis is to propose as-needed treatment depending on symptoms, rather than classical continuous treatment. This rostrum will discuss existing clinical trials on as-needed treatment for allergic rhinitis and real-world data obtained by the mobile health app MASK-air, which focuses on digitally-enabled, patient-centered care pathways. © 2022 American Academy of Allergy, Asthma & Immunology